Morgan Stanley upgrades Novartis stock rating to Equalweight on growth profile

Morgan Stanley upgraded Novartis (NVS) to Equalweight from Underweight, raising its price target to $100 from $91, citing an improved mid-term growth profile with projected 4% sales and EBIT growth for 2025-2028, surpassing peer Roche. The upgrade reflects potential upside from better commercial execution on key growth drivers, a promising catalyst path, and an effective bolt-on M&A strategy aimed at mitigating future loss of exclusivity challenges. Despite the upgrade, Morgan Stanley maintains a preference for AstraZeneca among European large-cap pharmaceuticals due to its perceived growth at a reasonable price and more manageable long-term LOE risk.

Analysis

Morgan Stanley has upgraded Novartis (NVS) to Equalweight from Underweight, increasing its price target to $100 from $91. The revision is predicated on an improved mid-term growth profile, with the bank projecting 4% sales and EBIT growth for Novartis between 2025-2028, favorably comparing to a 3% forecast for its peer, Roche. The upgrade also reflects confidence in potential upside from superior commercial execution of key growth drivers and a more promising catalyst pipeline. Strategically, Morgan Stanley views Novartis's bolt-on M&A approach, which targets mid-size assets in its core therapeutic areas, as an effective measure to counteract the significant loss of exclusivity (LOE) risks anticipated at the turn of the decade. Despite the more positive outlook for Novartis, the firm maintains its preference for AstraZeneca (AZN) within the European large-cap pharmaceutical space, citing AstraZeneca's combination of growth at a reasonable price and a more manageable long-term LOE risk profile.

Key Decisions for Investors

• The upgrade to Equalweight, while positive, suggests a neutral-to-constructive stance, indicating that current holders can justify maintaining their positions while awaiting evidence of enhanced commercial execution on key products.
• Investors should evaluate Novartis on a relative basis against peers, particularly AstraZeneca, which Morgan Stanley still prefers for its perceived superior growth-to-value proposition and lower long-term risk profile.
• Forward-looking performance will heavily depend on the successful execution of the company's bolt-on M&A strategy and its ability to deliver on the stated catalyst path to offset future loss of exclusivity pressures.